Why Nasus Pharma Ltd.’s (NSRX) Stock Is Up 5.71%
As of Wednesday, January 14, Nasus Pharma Ltd.’s NSRX share price has surged by 5.71%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Commentary & Analysis
Why Nasus Pharma Ltd.’s (NSRX) Stock Is Up 5.63%
As of Monday, January 12, Nasus Pharma Ltd.’s NSRX share price has surged by 5.63%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Nasus Pharma Ltd.’s (NSRX) Stock Is Up 10.32%
As of Thursday, January 08, Nasus Pharma Ltd.’s NSRX share price has surged by 10.32%, which has investors questioning if this is right time to sell.Tudor Pop
Why Nasus Pharma Ltd.’s (NSRX) Stock Is Down 9.60%
As of Wednesday, January 07, Nasus Pharma Ltd.’s NSRX share price has dipped by 9.60%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Nasus Pharma Ltd.’s (NSRX) Stock Is Down 11.69%
As of Tuesday, January 06, Nasus Pharma Ltd.’s NSRX share price has dipped by 11.69%, which has investors questioning if this is right time to buy.Tudor Pop
Financial Summary
| Share Statistics | NSRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $44.1 | $674.0 | 15% |
|
| Shares Out (Mil) | 11.1 | 43.9 | 22% |
|
| Institutional Ownership | 28.1% | 84.7% | 12% |
|
| Float (Mil) | 5.5 | 47.3 | 13% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 12 | 293 | 18% |
|
| Price Change (52-week) |
na | 68.8% | na |
|
| Growth | NSRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.8% | na |
|
| Net Income (5yr) | na | (1.5%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NSRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($11) | ($11) | 29% |
|
| EPS (TTM) | ($1.069) | ($0.700) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($7) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $33 | $575 | 14% |
|
| Valuation | NSRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.01 | 2.80 | 73% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NSRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.5% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (161.2%) | (24.6%) | 3% |
|
| ROE | (315.7%) | (21.4%) | 3% |
|
| Liabilities to Assets | 11.7% | 32.2% | 7% |
|
| F-Score | 3 | 3 | 18% |
|
Nasus Pharma Ltd. did not pass any screens on 9/2/2026.
